-
Mashup Score: 0Genetic Risk Score Offers Insight Into CLL Predisposition - 7 hour(s) ago
Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of #CLL. #leusm https://t.co/0jFaX8n1Bz https://t.co/xJJl70d5c5
-
-
Mashup Score: 2Revolutionizing CLL Care With Targeted and Cellular Therapies - 13 day(s) ago
Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Cyrus M. Khan, MD, (@CyrusKhann) highlights some of the most recent and significant advancements in #CLL treatment. #leusm | @AHNtoday https://t.co/yWyeD7lbOr
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Andrew H. Lipsky, MD, (@andrewlipskymd) moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with #CLL. #leusm | @ColumbiaMed @columbiacancer https://t.co/0OPUxg2be0 https://t.co/FWvpHKfzal
-
-
Mashup Score: 1BTK Inhibitor Therapy Can Be Stopped in CLL - 1 month(s) ago
The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Because BTK inhibitors rarely achieve deep responses as monotherapy and have relatively short half-lives, treatment break has been traditionally discouraged due to concerns of disease flare. #CLL #leusm Read more: https://t.co/fBjgWYMZgo
-
-
Mashup Score: 5
Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with #CLL and some of the available treatment options in this space. #LEUSM | @MDAndersonNews @SocietyofHemOnc https://t.co/00kOhlMqO5
-
-
Mashup Score: 4Behind the ELEVATE-TN Trial of Acalabrutinib/Obinutuzumab in CLL - 3 month(s) ago
Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: @jeff_sharman of @TheUSONetwork discusses the background of the ELEVATE-TN trial and its long-term efficacy data. #CLL #LEUSM https://t.co/rll42wdFDS
-
-
Mashup Score: 4
The combination of acalabrutinib and venetoclax with or without obinutuzumab improved survival vs standard chemotherapy in patients with previously untreated chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In patients with previously untreated #CLL, fixed-duration acalabrutinib + venetoclax, with or without obinutuzumab led to a stastically significant and clinically meaningful improvement in PFS in the phase 3 AMPLIFY trial. #LEUSM | @DanaFarber https://t.co/GmQ2rSdAnW
-
-
Mashup Score: 3Addressing Racial and Socioeconomic Disparities in CLL Care - 5 month(s) ago
In an interview, Ira Zackon, MD, emphasized the need for community-based, inclusive care, and the importance of utilizing technology to address disparities in the modern era of chronic lymphocytic leukemia treatment.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Ira Zackon, MD, underscores the imperative of community-based, inclusive care for chronic lymphocytic leukemia. Leveraging technology is pivotal in mitigating disparities across treatment landscapes. #CLL #leusm | @NYOHPC @TheUSONetwork https://t.co/8zPHPbwDPH
-
-
Mashup Score: 9
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
At a Case-Based Roundtable event, Stanley M. Marks, MD, led a discussion examining the repercussions of cardiac adverse events among patients with #CLL undergoing treatment with a BTK inhibitor. #leusm | @UPMCHillmanCC https://t.co/4C6ZDch1Kq https://t.co/O7YGI6wFs0
-
In an interview with Targeted Oncology, Susan L. Slager, PhD, discussed the etiology and inherited genetic factors that are associated with the risk of #CLL. #leusm | @MayoClinic https://t.co/fMXSiD0L91